Brain uptake and plasma metabolism of [11C]vinpocetine:: A preliminary PET study in a cynomolgus monkey

被引:37
作者
Gulyás, B [1 ]
Halldin, C
Karlsson, P
Chou, YH
Swahn, CG
Bönöck, P
Paróczai, M
Farde, L
机构
[1] Karolinska Inst, Dept Neurol, Div Brain Res, S-17177 Stockholm, Sweden
[2] Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, S-17177 Stockholm, Sweden
[3] Richter Gedeon Chem Works, Budapest, Hungary
关键词
positron emission tomography; brain; vinpocetine; metabolism;
D O I
10.1111/jon199994217
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Vinpocetine, a vinca alkaloid, is a widely used therapeutic agent in patients with acute and chronic stroke. To reveal the mechanisms of vinpocetine action in the brain, vinpocetine was labeled with (11)C. Positron emission tomography (PET) was used to determine the uptake and distribution of [(11)C]vinpocetine in brain regions and the trunk of a cynomolgous monkey in two independent measurements. The concentration of vinpocetine and its labeled metabolites was determined in blood and plasma using high-performance liquid chromatography (HPLC). Almost identical measurements were obtained in the two independent studies. After intravenous administration, following an initial peak, the total concentration of radioactivity in blood was relatively stable with time, whereas the concentration of the unchanged compound decreased with time in an exponential manner. The uptake of [(11)C]vinpocetine in brain was rapid, and 5% of the radioactivity totally injected was present in the brain 2 minutes after drug administration, indicating that the compound entered the brain readily. The radioactivity uptake was heterogeneously distributed among brain regions and was highest in the thalamus, the basal ganglia, and certain neocortical regions. The high brain uptake and the heterogeneous regional distribution indicate that direct central nervous system (CNS) effects of vinpocetine must be considered as explanation for the therapeutic effects. The detailed exploration of this suggestion requires further studies.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 32 条
[1]  
[Anonymous], 1995, DEV NUCL MED
[2]   Nootropic agent vinpocetine blocks delayed rectified potassium currents more strongly than high-threshold calcium currents [J].
Bukanova Yu.V. ;
Solntseva E.I. .
Neuroscience and Behavioral Physiology, 1998, 28 (2) :116-120
[3]   Vincamine and vincanol are potent blockers of voltage-gated Na+ channels [J].
Erdo, SL ;
Molnar, P ;
Lakics, V ;
Bence, JZ ;
Tomoskozi, Z .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 314 (1-2) :69-73
[4]   PET ANALYSIS OF HUMAN DOPAMINE RECEPTOR SUBTYPES USING C-11 SCH 23390 AND C-11 RACLOPRIDE [J].
FARDE, L ;
HALLDIN, C ;
STONEELANDER, S ;
SEDVALL, G .
PSYCHOPHARMACOLOGY, 1987, 92 (03) :278-284
[5]   PET STUDY OF [C-11] BETA-CIT BINDING TO MONOAMINE TRANSPORTERS IN THE MONKEY AND HUMAN BRAIN [J].
FARDE, L ;
HALLDIN, C ;
MULLER, L ;
SUHARA, T ;
KARLSSON, P ;
HALL, H .
SYNAPSE, 1994, 16 (02) :93-103
[6]   PET study of the M(1)-agonists [C-11]xanomeline and [C-11]butylthio-TZTP in monkey and man [J].
Farde, L ;
Suhara, T ;
Halldin, C ;
Nyback, H ;
Nakashima, Y ;
Swahn, CG ;
Karlsson, P ;
Ginovart, N ;
Bymaster, FP ;
Shannon, HE ;
Foged, C ;
Suzdak, PD ;
Sauerberg, P .
DEMENTIA, 1996, 7 (04) :187-195
[7]  
Gulyas B, 1998, NATO ASI 3 HIGH TECH, V51, P291
[8]  
HALLDIN C, 1995, J NUCL MED, V36, P1275
[9]  
HALLDIN C, 1990, APPL RADIAT ISOTOPES, V41, P669
[10]  
HAYAKAWA M, 1992, ARZNEIMITTEL-FORSCH, V42-1, P281